Speakers

The Organising Committee is pleased to announce the following confirmed speakers:

Keynote Speakers

Professor Roger Stupp MD

Professor Roger Stupp MDProfessor and Chairman, Department of Oncology & Director, University Hospital Cancer Center, University of Zurich, Zurich/Switzerland

Roger Stupp gained his MD at the University of Zurich. After training in oncology and hematology at the University of Chicago he spent 17 years as a physician and researcher at the University of Lausanne, Switzerland. Since 2013 he is the Director of the Department of Oncology and Cancer Center at the University Hospital in Zurich. He also serves as the President of the European Organisation for Research and Treatment of Cancer (EORTC), the prime cooperative group conducting clinical trials and translational research throughout a pan-European network of over 200 active universities and academic medical centers. Dr. Stupp’s research focuses on early drug development, the combination of chemo- and radiotherapy, multidisciplinary cancer management, namely in the areas of lung cancer and brain tumors. He is involved in bringing new antiangiogenic and biological treatments to the clinic. Dr. Stupp is or has been the principal investigator for large multimodality clinical trials in brain tumors and non-small cell lung cancer. His work has been extensively published in such journals as The New England Journal of Medicine, Lancet Oncology, Clinical Cancer Research, Molecular Oncology, Neuro-Oncology, the European Journal of Cancer, and the Journal of Clinical Oncology, among others.

Dr. Stupp is associate and section editor for the European Journal of Cancer, and is a member of the editorial board of several oncology journals. He also serves in scientific or educational committees of the European Society of Medical Oncology (ESMO) and the American Society of Clinical Oncology (ASCO); he also acts as a council for several European and National funding agencies.

Dr. Stupp has received several awards, most recently  the Victor Levin Award by the Society of Neuro-Oncology in the USA, and the Hamilton Fairley Award by the European Society of Medical Oncology in 2013.

Professor Mitchel Berger MD FACS FAANS

Professor Mitchel Berger MD FACS FAANSProfessor and Chairman, Department of Neurological Surgery, UCSF, USA

Mitchel Berger is the Kathleen M. Plant Distinguished Professor and Chairman of the Department of Neurological Surgery at the University of California, San Francisco (UCSF), and is an expert in the fields of neurosurgery and neuro-oncology. He also serves as Director of UCSF’s Brain Tumor Research Center and Neurosurgical Research Centers.

After graduating from Harvard University in 1974, Dr. Berger earned his medical degree from the University of Miami School of Medicine. He completed a clinical fellowship in neuro-oncology at UCSF, a fellowship in pediatric neurosurgery at the Hospital for Sick Children of the University of Toronto, and his neurosurgical residency at UCSF. In 1986, he became Assistant Professor of Neurosurgery at the University of Washington School of Medicine, after which he was named Associate Professor (1990) and Professor (1996).

Dr. Berger has clinical expertise in treating adult and pediatric brain and spinal cord tumors.  He is a pioneer of intraoperative brain mapping — a technique used to avoid functional areas of the brain during surgical resection of a tumor.  His work has enabled surgeons to perform more extensive resection of tumor with less chance of producing sensorimotor or language deficit.

Dr. Berger is a leader of translational research and is the Principal Investigator of the UCSF Brain Tumor Research Center’s Specialized Program of Research Excellence (SPORE) award in neuro-oncology, funded by the National Institutes of Health. He is also the Principal Investigator of the Pediatric Brain Tumor Foundation Institute at UCSF – a world-class research program dedicated to defining the poorly understood basic biology of several types of childhood brain tumors and improving therapies.

His specific research interests lie in identifying molecular markers related to the progression and prognosis of glial tumors, as well as the development of small-molecule therapeutic agents that can be administered directly to the brain via convection-enhanced drug delivery.  Dr. Berger is also a co-investigator at UCSF’s Comprehensive Cancer Center, where he works to develop immunoliposome-directed targeted therapy for treating gliomas that express epidermal growth factor receptors.

Dr. Berger is a member of the Board of Directors of the American Association of Neurological Surgeons and the American Board of Neurological Surgery. In 2009, he was awarded the prestigious Winn Prize by the Society for Neurological Surgery. He is currently Secretary of the American Academy of Neurological Surgery. He also currently serves as a member of the National Football League Head, Neck and Spine Committee, focusing on retired players’ issues and examining the consequences of repetitive head injury and concussion.

During his distinguished career, Dr. Berger has served as President of the American Association of Neurological Surgeons, President of the Society of Neuro-Oncology, President of the North Pacific Society of Neurology, and Vice President of the Congress of Neurological Surgeons. He is an active member of numerous professional organizations, including the American Organization for Cancer Research, the American College of Surgeons, and the World Federation of Neurosurgical Societies. 
 
A prolific author, Dr. Berger has contributed over 450 scientific articles to peer-reviewed journals, has edited 6 textbooks, and has written over 80 chapters on various neurosurgical topics. He is currently on the editorial boards of several leading journals including Neuro-Oncology, Neurosurgery, and American Journal of Translational Research.
Professor Paul Mischel MD

Professor Paul Mischel MDHead, Laboratory of Molecular Pathology, Ludwig Institute for Cancer Research, USA
Professor, University of California San Diego, USA

Paul Mischel’s research is directed at defining the signal transduction and metabolic networks that promote tumor growth, focusing primarily on EGFR/PI3K/mTOR signaling and its biochemical consequences. The Mischel group has a particular interest in glioblastoma, tightly integrating studies in pre-clinical models with analyses of patients treated in state of the art clinical trials, with the goal of developing more effective, less toxic therapies. Recently, his group has also become particularly interested in the role of extrachromosomal DNA in cancer.

Dr. Mischel received his M.D. with honors (Alpha Omega Alpha) from Cornell University Medical College. He did residency and fellowship training in Anatomic Pathology and Neuropathology at the University of California, Los Angeles and followed his clinical training with a post-doctoral research fellowship in the laboratory of Dr. Louis Reichardt, at the Howard Hughes Medical Institute at University of California San Francisco. Dr. Mischel joined the faculty of UCLA in 1998, becoming the Lya and Harrision Latta Professor of Pathology and Laboratory. In August of 2012, Dr. Mischel was recruited to the Ludwig Institute for Cancer Research, San Diego Branch.

Dr. Mischel was elected to the American Society for Clinical Investigation (ASCI) and the American Association of Physicians, and he served as the Past-President of the American Society for Clinical Investigation (ASCI). He currently serves on editorial boards of several journals and on a number of scientific advisory boards.  

Dr. Mischel has published 161 scientific papers and he is the recipient of a number of honors, including The Farber Award for Brain Cancer Research. He has also been recognized as one of “America’s Top Doctors” for Cancer and for Pathology (Castle and Connolly and US News and World Report).

Associate Professor Arjun Sahgal BSc MD FRCPC

Associate Professor Arjun Sahgal BSc MD FRCPCAssociate Professor of Radiation Oncology and Surgery, University of Toronto, Canada
Deputy Chief, Department of Radiation Oncology, Odette Cancer Centre, Canada

Arjun Sahgal is a leader in the field of high precision stereotactic radiation to the brain and spine. After training at the University of Toronto in radiation oncology, he completed a fellowship at the University of California San Francisco in brain and spine radiosurgery with Professor Dr. David Larson. Since then he has been recognized as a national and international clinical expert and research leader in radiosurgery. His main focus is on developing spine stereotactic body radiotherapy (SBRT) as an effective therapy for patients with spinal tumors. He has published numerous peer reviewed papers and book chapters on the subject. He has already published over 100 peer reviewed papers including high impact journals like Journal of Clinical Oncology and Lancet Oncology, editor and writer of several books specific to research on brain and bone metastases, editorial board member for several journals, past-chairman of the International Stereotactic Radiosurgery Society meeting held June 2013, and board member for the Brain Tumour Foundation of Canada and the International Stereotactic Radiosurgery Society. He has been invited internationally to speak at several meetings and to various universities as a visiting professor, and leads several research groups. His further research activities involve integrating MRI into radiotherapy delivery, combining novel pharmacologic therapies with radiosurgery, and MRI-Guided focused ultrasound.

Professor W. K. Alfred Yung MD

Professor W. K. Alfred Yung MDProfessor and Chair of Neuro-oncology, The University of Texas MD Anderson Cancer Center, USA

W. K. Alfred Yung is professor and chair of Neuro-oncology at The University of Texas MD Anderson Cancer Center, where he holds the Margaret and Ben Love Chair of Clinical Cancer Care and dual appointment as professor of cancer biology. He is also a professor of neurology at the University of Texas (UT) Health Sciences Center at Houston Medical School and a faculty member at the UT Graduate School of Biomedical Sciences in Houston.

He earned his undergraduate degree from the University of Minnesota, Minneapolis and his medical degree from the University of Chicago Pritzker School of Medicine. Internship and residency training followed at the University of California, San Diego. He completed chief residency and a fellowship at Cornell University School of Medicine and Memorial Sloan-Kettering Cancer Center. Dr. Yung joined MD Anderson as assistant professor in 1981 and rose quickly through the faculty ranks.

His many roles at MD Anderson have included deputy chair of Neuro-Oncology and medical director of the Neuro and Supportive Care Center. In 2001, he became co-director of our renowned Brain Tumor Center, which he expanded with co-director Raymond Sawaya, M.D. Dr. Yung has led the department of Neuro- Oncology as ad interim chair (1999-2002) and as chair since 2003. During his tenure, the department has launched fellowship programs in neuro-oncology and neuro-psychology and expanded to 24 faculty who have achieved much under his guidance, including development of the National Cancer Institute (NCI)-funded Brain Specialized Program of Research Excellence, building of the groundbreaking D24 smart oncolytic virus program, leadership in the NCI-funded CNS tumor clinical trial consortia and creation of the Brain Tumor Trial Collaborative.

Dr. Yung’s extensive experience and expertise in brain tumor research has included nearly three decades of basic, translational and clinical studies at MD Anderson. Published in more than 300 peer-reviewed journals, his research aims to develop new therapeutic approaches to block the regulatory mechanisms of brain cancer cells. His primary focus is on development of molecular therapeutic strategies targeting the EGFR and PTEN/PI3 kinase pathways and the angiogenic regulatory mechanisms that are crucial to the genesis and progression of human glioma. Dr. Yung’s many significant contributions to his field include leadership of the study that led to FDA approval of temozolomide for glioblastoma and co-leadership of the registration study which led to approval of the drug bevacizumab for recurrent glioblastoma. His work has been advanced by 30 years of continuous funding by NCI as well as support from numerous foundations and industry grants.

Respected nationally and internationally, Dr. Yung has served his profession in numerous leadership roles, including editor-in-chief of Neuro-Oncology, the flagship journal of the Society of Neuro-Oncology, from 2007-2014, and co-chair of the NCI Brain Malignancy Steering Committee since 2011.

Professor Gregory Riggins MD PhD

Professor Gregory Riggins MD PhDProfessor of Neurosurgery and Oncology, Johns Hopkins University School of Medicine, USA

Gregory Riggins is the inaugural Irving J. Sherman M.D. Research Professor of Neurosurgery and Oncology at Johns Hopkins University School of Medicine. He is the director of the Brain Cancer Biology and Therapy Laboratory at Johns Hopkins School of Medicine, started in 2003 and the director of the division of neurosurgery research. The Brain Cancer Biology and Therapy Laboratory is a translational cancer research lab for brain and other cancers.  His laboratory has helped develop cancer therapies based on drug repurposing, drug combinations, novel targeted therapy, bacteria based immunotherapy, and cancer prevention. The first phase 1 clinical trial from his work has demonstrated that an improved formulation of mebendazole is safe in high doses and in combination with Temozolomide for newly diagnosed patients with glioblastoma.  Evidence from this trial suggests further investigation as a phase 2 trial. A first in human phase 1 safety trial for the novel procaspase 3 activator, PAC-1, (first developed at the University of Illinois) has opened.  The trial will include a component for newly diagnosed glioblastoma based on the work from the Brain Cancer Biology and Therapy Laboratory. In addition to the new therapies for glioblastoma, a major area of active research is the development of improved therapeutic approaches for IDH mutant gliomas.

Assistant Adjunct Professor Mary Lovely PhD RN CNRN

Courtesy of Brain Tumour Alliance Australia

Assistant Adjunct Professor Mary Lovely PhD RN CNRNAssistant Adjunct Professor, UCSF School of Nursing, USA

Mary Lovely earned her PhD at the University of California San Francisco (UCSF) School of Nursing focusing on symptom management and brain tumor patient care.  During her Post Doctoral Fellowship she studied the effects of fatigue on brain tumor patients.

Dr. Lovely developed a program of research around long-term effects experienced by patients and families with brain tumors.  She has numerous presentations and publications as Assistant Adjunct Professor in the UCSF School of Nursing.

Dr. Lovely has held positions with the American Brain Tumor Association and the National Brain Tumor Society.  In these roles, she communicated with patients and families about clinical issues throughout the United States, and developed conferences for patients and healthcare professionals. She consults for Tocagen as a patient support liaison.
 
Dr. Lovely co-facilitates an active brain tumor support group in San Francisco, and reviews prospective articles for many journals.  She presently consults for patients and families dealing with cognitive issues following cancer.

She is First Author for Clinical Nursing Practice Guidelines for Adult Brain Tumor Patients through the American Association of Neuroscience Nurses.


Invited Speakers

Professor Meera Agar

Meera Agar MeerawebProfessor Meera Agar is Professor of Palliative Medicine, Centre for Cardiovascular and Chronic Disease, University of Technology Sydney.

She is a Palliative Medicine Physician and is the research lead for the South West Sydney Palliative Care Clinical Trials unit and the Clinical trials director, Ingham Institute of Applied Medical Research. Her research interests include delirium in advanced cancer, dementia end-of-life care, pharmacological and health service randomised controlled trials in palliative care and neuro-oncology supportive and palliative care research. She is the Chair of ImPACCT (Improving Palliative Care through Clinical Trials), the NSW collaborative trials group in palliative care.

 

 

Dr Brian Alexander

Brian Alexander PhotoDisease Center Leader, Radiation Oncology, Center for Neuro-Oncology – Dana-Farber Cancer Institute, Harvard Medical School

Brian Alexander, MD, MPH, is a radiation oncologist specializing in research and clinical care for patients with tumors of the central nervous system, and is the Director of the Neuro-Radiation Oncology Program at the Brigham and Women’s/Dana-Farber Cancer Center. His research interests include the characterization of the radiation responsiveness of glioma stem cells, preclinical evaluation of novel therapeutics, and innovative designs for early phase clinical trials.

Dr. Alexander previously served as a White House Fellow and Special Assistant to the Secretary of Veterans Affairs from 2008-2009. Under Secretary Peake, he helped prepare VA for the transition of administrations and worked to develop a public reporting system for quality performance indicators that formed the foundation for VA ASPIRE. During the transition and the early part of the Obama administration, Dr. Alexander served as a health policy advisor to Secretary Shinseki. In that role, he led the Department’s effort to organize the International Roundtable on Clinical Quality and Patient Safety and coordinated all aspects of Secretary Shinskei’s preparation for the Obama Administration’s Health Care Summit.
In addition to his role as health policy advisor, Dr. Alexander organized the standup of the VA’s Coordinating Council on National Health Reform and directed the activities of its multi-team Health Reform Working Group. Dr. Alexander is currently a member of the Institute of Medicine’s Committee on the Governance and Financing of Graduate Medical Education.

Dr. Alexander is originally from Southfield, Michigan and is a graduate of Kalamazoo College, the University of Michigan Medical School, and the Harvard School of Public Health.

 

 

Dr Tiara Aninditha

Tiara Aninditha PhotoHead of Neuro-Ooncology, Headache, and Pain Division,
Neurology Department, Faculty of Medicine, University of Indonesia

Tiara Aninditha, a Neuro-Oncologist consultant, is currently the Head of Neuro-Oncology,
Headache, and Pain Division in Neurology Department, Faculty of Medicine University of
Indonesia.
Following completion of her residency at Neurology Department Faculty of Medicine University of Indonesia in 2006, she joined the medical staff in that university in 2007. Together with her professor, she established the Neuro-Oncology division in her department and running the Neuro-Oncology module, the first and the only Neurology residency program in Indonesia.

They also expanded the Neuro-Oncology program wide scaled for other Neurologists in Indonesia by developing the Neuro-Oncology study group of Indonesian Association of Neurology, which now she has become the Vice Director of. She received her doctor degree in Biomedic from the University of Indonesia in 2012. Her research focused on tissue factor and vascular endothelial growth factor in meningioma. She is also the editor in chief of Neurona, the only national medical journal with latest Neuroscience development in Indonesia.
One of her main interest in Neuro-Oncology is in implementing a comprehensive and multidisciplinary approach in cancer care. Now, she is one of the founders of Indonesian Society of Neuro-Oncology (InaSNO), the first national Neuro-Oncology association in Indonesia, that was been established last year.

Dr Anna D. Barker

Anna Barker PhotoCo-Director, Complex Adaptive Systems (CAS)
Director, Transformative Healthcare Knowledge
Director, National Biomarker Development Alliance
Professor, School of Life Sciences, Arizona State University

Dr. Barker is co-director of Complex Adaptive Systems at Arizona State University (ASU), which serves as an organizing construct to understand and solve multidimensional problems in the biomedical sciences and biomedicine. She develops knowledge networks that leverage convergent knowledge in the biological and physical sciences, innovative teams, and novel funding approaches to better prevent and treat acute and chronic diseases.

Prior to joining ASU, Dr. Barker served for several years as the deputy director of the National Cancer Institute (NCI) where she developed and implemented strategic transdisciplinary programs, including: the Nanotechnology Alliance for Cancer; The Cancer Genome Atlas (TCGA) (in collaboration with the National Human Genome Research Institute); the Clinical Proteomics Technologies Initiative for Cancer; the Physical Sciences-Oncology Centers; and national initiatives in biospecimen best practices and bioinformatics. All of these programs emphasize the synergy of large- scale and individual-initiated research; precompetitive collaboration; publically available data; and clinical translation to more effectively detect, prevent, and treat cancer. She also oversaw the NCI’s international cancer research programs, including pilot programs in Latin America and China. Dr. Barker was the founding co-chair of the NCI-FDA Interagency Task Force, founding co-chair of the Cancer Steering Committee of the Foundation for the National Institutes of Health (FNIH) Biomarker Consortium, and founding director of the NBDA. She has a long history in research and in the leadership and management of research and development in the academic, nonprofit, and private sectors.

Dr. Barker served as a senior scientist and subsequently as a senior executive at Battelle Memorial Institute for 18 years and cofounded and served as the CEO of a public biotechnology drug development company. She has received a number of awards for her work in support of cancer research, cancer patients, professional and advocacy organizations, and the ongoing national effort to prevent and cure cancer. Dr. Barker’s research interests include complex adaptive systems, evolutionary medicine, and free-radical biochemistry in cancer etiology and treatment. She completed her MA and PhD degrees at The Ohio State University, where she trained in immunology and microbiology.

 

 

Dr Julette Batara

Clinical Associate Professor Head, Neurology ICU
Assistant Chair for Emergency Room Services
Neuro-Oncology Service
Department of Neurosciences
Philippine General Hospital, Manila, Philippines

Neurologist with subspecialty in Neuro-Oncology
St. Luke’s MEDICAL CENTER Quezon City and Bonifacio Global City, Philippines

President, Philippine Society for Neuro-Oncology Training

Neuro Oncology Fellowship: Johns Hopkins Medical Institutions, Baltimore, Maryland USA
Medical School: University of the East Ramon Magsaysay Memorial Medical Center, Quezon City, Philippines Neurology Residency: University of the Philippines Philippine General Hospital, Manila, Philippines

Previous Positions/Work:
Head, Comprehensive Brain Tumor Center, St Luke’s Medical Center, Quezon City, Philippines

 

Professor Donald Berry

Donald Berry PhotoFounder and Senior Statistical Scientist, Berry Consultants, LLC
Professor, Department of Biostatistics, The University of Texas MD Anderson Cancer Center

Dr. Berry is a professor in the Department of Biostatistics of The University of Texas MD Anderson Cancer Center. He was founding chair of this department in 1999 and
founding head of the Division of Quantitative Sciences, including the Department of Bioinformatics and Computational Biology, in 2006. Dr. Berry received a PhD degree in
statistics from Yale University and previously served on the faculties of the University of Minnesota and Duke University. He held endowed faculty positions at Duke University and at MD Anderson. Since 1990

Dr. Berry has served as a faculty statistician on the Breast Cancer Committee of the Cancer and Leukemia Group B, a national oncology group. He has designed and supervised the conduct of many large US intergroup trials in breast cancer. A principal focus of Dr. Berry’s research is the use of biomarkers in cancer and other diseases for learning which patients benefit from which therapies, based on genomics and phenotype. He designed and is a co-PI of I-SPY 2 (www.ispy2.org), a Bayesian adaptive platform clinical trial in high-risk early breast cancer whose goal is matching experimental therapies with patient subsets defined by tumor molecular characteristics.

Since 1997 Dr. Berry has served on the NCI’s PDQ Screening and Prevention Board, for which he received the NIH Award of Merit in 2010. Through Berry Consultants, LLC, he has designed many innovative clinical trials for pharmaceutical and medical device companies and for NIH cooperative groups. Dr. Berry is the author of several books on statistical methodology and over 300 published articles, including first-authored articles in the major medical journals. He has been the principal investigator for numerous research grants from the NIH and the National Science Foundation and is a fellow of the American Statistical Association and the Institute of Mathematical Statistics.

 

 

Ms Vivien Biggs

Viv Biggs PhotoVivien Biggs has over 25 years experience working in Neurosurgery in both Sydney and Brisbane.
She has a Post-graduate certificate in Neuroscience Nursing and a Masters of Nursing Science (Nurse Practitioner).
She has worked in both public and private practice and joined the Neurosurgical team at BrizBrain and Spine in 2007. The role was originally as a Care Coordinator for brain tumour patients and their families and from 2010 the role evolved to her current position as Neuro-Oncology Nurse Practitioner.

Vivien’s role also involves working with the research nurses at the Newro Foundation assisting with patient recruitment and assessment for their scientific and psychosocial research projects.
She lectures to under graduate and post graduate nurses on Neurological Nursing at the Queensland University of Technology.

Associate Professor Andrew Cole

AMDC 1104A/Professor Andrew Cole has been a Consultant in Rehabilitation Medicine and a conjoint UNSW academic since 1985, working as HammondCare’s Chief Medical Officer since 2008. He is President of the Australasian Faculty of Rehabilitation Medicine.
His interests lie in rehabilitation of cancer and neurological disability, and providing rehabilitation care for very frail older people, at Greenwich Hospital.

In Australia, Andrew teaches about disability and ageing to UNSW medical students and rehabilitation trainees. He has regularly taught these topics to medical, nursing and allied health staff during visits to East Asia in the last decade.

Andrew maintains life balance by spending time with his family members, playing classical organ music, learning Chinese, enjoying steam trains and doing practical jobs around the home and garden.

 

 

Professor Timothy Cloughesy

Timothy Cloughesy PhotoProfessor, Neurology, David Geffen School of Medicine at the University of California, Los Angeles.

Dr. Cloughesy is a Professor of Neurology at the David Geffen School of Medicine at UCLA. He received his BA degree with Honors in Chemistry in 1983 at University of California, Santa Barbara, and his MD degree in 1987 at Tulane University. He completed his Neurology Residency at University of California, Los Angeles and fellowships in Clinical Neurophysiology (UCLA 1991- 1992) and Neuro-Oncology (Memorial Sloan Kettering Cancer Center 1992).
Dr. Cloughesy is board certified in Neurology and Clinical Neurophysiology. He joined the faculty of the David Geffen School of Medicine at UCLA in 1992 with the Department of Neurology.

He is the director of the Neuro-Oncology Program at UCLA and the Director of the Henry Singleton Brain Cancer Research Program. He is a member of the Brain Research Institute and Jonsson Comprehensive Cancer Center at UCLA.
Dr. Cloughesy’s research has focused on clinical trials in brain cancer using targeted molecular therapies with novel clinical trial design and biomarkers in brain cancer.  He provided principal leadership for the approval of bevacizumab for recurrent glioblastoma. This was the first drug approved for recurrent glioblastoma in over 30 years.
He is recognized as a world expert in the brain cancer research and has been asked to lead several first-in-human studies to treat glioblastoma. He has developed a brain cancer bioinformatics database which combines clinical outcomes, imaging, and molecular analysis to enhance translational research and has the goal of using biomarkers to provide individualized care for brain cancer patients. He has authored or co-authored over 200 peer-reviewed articles on brain cancer.

 

Ms Marcia Fleet

Marcia FleetMs Marcia Fleet is a Cancer Care Coordinator in the Neuro-Oncology unit at Royal Melbourne Hospital. 

Trained as a radiation therapist and worked for many years in departments in Victoria and NSW. This  experience of many years in oncology works well with the care coordination position.
In the CCC position she works with the medical staff to support the patients and their families from before diagnosis often to end of life. She is the go to person within the unit and runs a support group for patients with high grade tumours.

 

 

Associate Professor Matthew Foote

Matthew FooteAssociate Professor Foote is a Radiation Oncologist at the Princess Alexandra Hospital, Brisbane.  He is a full time academic clinician (teaching and research) since his appointment as a Staff Specialist in 2010. 

Associate Professor Foote established and is Co-director of the Gamma Knife® Centre of Queensland, the only public unit in Australia providing Gamma Knife® radiosurgery for brain tumours.  Having completed his advanced training in Radiation Oncology in 2009, Assoc Prof Foote commenced a neuro-oncology and stereotactic fellowship at the Princess Margaret Hospital, Toronto, Canada.  He now has an established clinical and translational research program with multiple national and international collaborations, serving as study chair on both national and international clinical studies.

 

 

Associate Professor Fabio Iwamoto
Professor Rakesh Jalali

Rakesh JalaliRakesh Jalali leads the Neuro-Oncology Group in TMH, finest and premier such unit in India drawing patient referral, training opportunities, observers and research project requests and funding. His research interests has focused on evaluation of high-precision techniques of radiotherapy, late-term toxicities and quality of life, biological imaging, molecular prediction and clinical evaluation of new agents in neuro-oncology. He has more than 200 publications to his credit.

Dr Jalali was instrumental in establishing the Indian Society of Neuro-Oncology (ISNO) in 2008 serving as its founding general secretary and now currently as its President. He is leading two national expert panels on formulating ISNO guidelines for ‘medulloblastomas’ (2015-16) and ‘WHO 2016 classification of CNS tumours and clinical impact’ (2016-17). As President of ASNO, he hosted its annual meeting in March 2013 in Mumbai with more 650 attendees. Dr Jalali’s honours include awards in Pediatric Clinical Research and Quality of Life Research at the SNO Annual Meetings and has delivered countless lectures at various scientific and social forums. He is currently ASNO’s co-editor of Neuro-Oncology Practice and webmaster of ASNO’s website.

Dr Jalali also runs the ‘Brain Tumour Foundation of India’, a charity dedicated to the welfare of the patients with brain tumours and their families. He also conceptualised and helped make an animation film for children with cancer, ‘Bust That Noma’, to alleviate some of the anxieties suffered by children undergoing cancer treatment. 

Dr Ben Jonker

Ben JonkerDr Ben Jonker is a neurosurgeon based in Sydney. He completed his neurosurgical training in Australia, and subsequently undertook subspecialty training in Stereotactic and Functional Neurosurgery (including stereotactic radiosurgery) in Calgary, Canada and UCLA, Los Angeles.
 
Dr Jonker has a particular interest in conditions treated with stereotactic and functional neurosurgery – and treats these with both conventional neurosurgery and stereotactic radiosurgery.
His main interests are brain and pituitary tumours including awake surgery and brain mapping, trigeminal neuralgia, movement disorder surgery and endoscopic surgery for hydrocephalus.

 

 

Dr Mustafa Khasraw

Mustafa Khasraw PhotoDr Mustafa Khasraw acts at the NHMRC Clinical Trials Centre of The University of Sydney as a senior research fellow and clinical lead for the Cooperative Trials Group for Neuro-Oncology (COGNO). In addition, Dr Khasraw is a medical oncologist at Royal North Shore Hospital and over the previous 5 years he worked in Geelong as a medical oncologist and cancer research fellow at Deakin University with leading role in several clinical and translational laboratory programs.
After his medical oncology training in Sydney he undertook an oncology fellowship training in the US at Memorial Sloan-Kettering Cancer Centre in New York. His fellowship was both in neuro-oncology and in breast cancer.
Mustafa Khasraw is leading several multi-centre clinical trials and he acts regularly as a reviewer for a number of scientific journals and grant review committees.

Dr Eng-Siew Koh

Dr Koh photoDr Eng-Siew Koh is a consultant Radiation Oncologist based at Liverpool Cancer Therapy Centre, Liverpool Hospital, NSW. She qualified in Medicine at the University of Adelaide then completed her specialty training at Westmead Hospital. She undertook a three year Fellowship at the Princess Margaret Hospital, and the Hospital for Sick Children, University of Toronto, Canada, in the areas of adult and paediatric neuro-oncology and stereotactic radiotherapy, and also haematologic and breast malignancies.

Her clinical and research interests include neuro-oncology imaging, cognitive and behavioural sequelae in brain tumours, and clinical neuro-oncology care coordination. Dr Koh has a particular research interest in cancer survivorship and the study of late effects of cancer treatment in both adult and paediatric cancer patients, in particular, the induction of secondary malignancy.

She is the current chair of the Clinical Oncological Society of Australia (COSA) Neuro-oncology group and is a member of the COGNO Scientific and Management Advisory Committees.

 

Dr Danette Langbecker

Danette Langbecker photo 1Dr Danette Langbecker is an NHMRC Research Fellow at the Centre for Online Health, The University of Queensland.  Her overall program of research to date has focused on investigating how best to support cancer patients and their families, with a focus on people affected by brain tumours. She completed a PhD at the Queensland University of Technology that involved developing and testing a patient-focused resource to encourage communication between health professionals and patients and families affected by brain tumours, and she continues to develop this program of research with colleagues in Australia and internationally.

Danette’s research within the COH focuses on the development and testing of an online intervention to improve self-efficacy to care and reduce caregiver burden and distress among family members of adults with primary brain tumours. Another stream of research focuses on understanding the impacts and supportive care needs of long term brain tumour survivors and their family members. Danette is also am supporting ongoing research in the COH in the areas of online health and telehealth, investigating applying new technologies to improve models of care for people with a range of conditions.

Professor Guiseppe Minniti

giuseppe minniti 2Dr. Giuseppe Minniti is a Professor of Radiation Oncology at Sant’Andrea Hospital, University of Rome “La Sapienza”. He is also a Honorary Neuro-oncology Consultant at IRCCS Neuromed and Scientific Consultant for Neuro-oncology at the University of Pittsburgh Medical Center (UPMC), San Pietro Hospital.

His main interests are brain tumors, chemotherapy and radiotherapy for primary and secondary brain tumors, stereotactic radiotherapy and radiosurgery. He has authored more than 130 publications on indexed international medical journals. He is a member of the European Society for therapeutic Radiology and Oncology (ESTRO), Italian Society of Radiotherapy (AIRO), Italian Society of Neurooncology (AINO), European Association of Neuro-Oncology (EANO) and European Organisation for Research and Treatment of Cancer (EORTC) – Brain Tumour Group.

 

 

Professor Anna Nowak

Anna-Nowak-photoProfessor Anna Nowak is an academic Medical Oncologist at Sir Charles Gairdner Hospital in Western Australia, and Professor of Medicine in the School of Medicine and Pharmacology, University of Western Australia.
Her clinical and research interests are in malignant pleural mesothelioma and neuro-oncology, with a PhD in tumor immunology and post-doctoral fellowship in clinical trials research giving her a niche as a ‘bench to bedside’ researcher who has implemented findings from her laboratory into first-in-man clinical trials. She has been a member of COGNO since its inception and her research in high grade glioma focuses on active participation in clinical trials and collaboration on psychosocial and supportive care research questions, as well as being co-chair of the AGOG tissue banking and genetic epidemiology project and the newly formed Brain Cancer Biobanking Australia.

In her association with COGNO, she is a member of the Scientific Advisory Committee, and is currently the Australian PI of the EORTC CATNON clinical trial, and Trial Management Committee Member of the completed CABARET study. She has been site principal investigator of numerous clinical trials in high grade glioma at Sir Charles Gairdner Hospital. Prof Nowak leads the neuro-oncology service at Sir Charles Gairdner Hospital, which sees around 130 new patients a year with glioma, and is committed to maximizing participation o

 

Sona Pungavkar

Sona PungavkarChief of MRI and CT department, Global Hospitals, Mumbai. 
It is a tertiary care hospital close to the largest Cancer Centre in India – Tata Memorial Hospital.
She has a special interest in Neuro-Onco-Radiology where she has dedicated more than 14 years, working closely with Disease Management Group led by Dr. Rakesh Jalali at Tata Memorial Hospital.

She has pioneered MR Spectroscopy, MR Perfusion and 3D Arterial Spin Labelling in India and trained in Grant Medical Hospital and Lokmanya Tilak Hospitals in  Mumbai. 

She has also trained for MR Spectroscopy Services, with Dr Brian Ross, Pennysylvania.
A founding member of Indian Society of Neuro-oncology.
Currently the treasurer of Indian Society of Neuro-oncology.
Teaching experience for more than six years for Radiology students.
Several national and international lectures and publications.
Author of two chapters in text books.
Author for a Karl Storz publication on ENT.

Professor Mark Rosenthal

rosenthal_markProfessor Mark Rosenthal trained as a Medical Oncologist in Melbourne and Sydney, Australia.
He was awarded a Doctorate of Philosophy for a thesis examining the molecular genetics of colon cancer conducted at the Ludwig Institute for Cancer Research. (1992-1996).

He completed post-graduate training at New York University Medical Centre, New York, USA (1996-98) and was appointed as a Senior Staff Specialist in the Department of Medical Oncology, Royal Melbourne Hospital in 1998. In 2006, he was appointed Professor Director of the Department and was Chairman and Chief Medical Officer of Cancer Trials Australia until 2016 when he was appointed as Director of the Victorian Comprehensive Cancer Centre Clinical Trials Unit. 

He is Chairman of the Cooperative Trials Group for Neuro-Oncology (COGNO). His major interests include: prostate cancer, neuro-oncology and early phase clinical trials.

 

Associate Professor Sith Sathornsumetee

Sith SathornsumeteeAssociate Professor of Medicine
Faculty of Medicine Siriraj Hospital
Mahidol University, Bangkok, Thailand

Sith Sathornsumetee, MD, is an Associate Professor of Medicine and Director of the Neuro-oncology Program in the Department of Medicine at the Faculty of Medicine Siriraj Hospital, Mahidol University, in Bangkok, Thailand.

Dr. Sathornsumetee received his medical degree from the Faculty of Medicine at Siriraj Hospital, Mahidol University. He completed his research training in neuro-immunology at Mayo Clinic College of Medicine in Rochester, Minnesota, and then his neurology residency and neuro-oncology fellowship at Duke University Medical Center in Durham, North Carolina, USA.

An active contributor to medical literature, Dr. Sathornsumetee has published more than 80 full-length manuscripts, invited reviews, and international book chapters. In addition, he is also a reviewer for several international journals and granting agencies.
Dr. Sathornsumetee has focused his research on the development of novel therapeutics for brain tumors in several areas, including preclinical evaluation, clinical trials, and biomarker identification. In addition, he has explored the role of glioma stem cells in angiogenesis, invasion and therapeutic resistance.

Dr Tim Solberg

solberg_picTimothy Solberg received his master of science degree in physics from the University of California, Davis, and his PhD in biomedical physics from the University of California, Los Angeles (UCLA).
His areas of specialization include radiation therapy physics, stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT), image-guided radiotherapy (IGRT), optimization and intensity-modulated radiotherapy, and radiation transport methods. He was named a fellow of the American College of Medical Physics (ACMP) in 2005, the American Association of Physicists in Medicine (AAPM) in 2006, and the American College of Radiology (ACR) in 2013. Dr. Solberg is a licensed medical physicist and is certified in therapeutic radiological physics by the American Board of Radiology.

Dr. Solberg received his initial faculty appointment in the Department of Radiation Oncology at UCLA in 1996, and went on to hold the positions of professor, vice chair, and co-director of the Radiosurgery Program at UCLA. He was Director of Medical Physics and Barbara Crittenden Professor of Cancer Research in the Department of Radiation Oncology at the University of Texas Southwestern Medical Center in Dallas from 2008-2013, and Professor and Vice Chair in the Department of Radiation Oncology at University of Pennsylvania in Philadelphia from 2013-2016.
Dr. Solberg is currently a Professor, Vice Chair and Director of Medical Physics in the Department of Radiation Oncology at University of California, San Francisco. He is actively involved in numerous professional societies, including the AAPM, ACR, American Society for Therapeutic Radiology and Oncology (ASTRO), European Society for Therapeutic Radiology and Oncology (ESTRO), and others. He is deputy editor-in-chief for the Journal of Applied Clinical Medical Physics, and reviews manuscripts for many other journals. He has authored over 180 papers, over 350 abstracts, 28 book chapters, 1 book (on stereotactic radiosurgery and SBRT), and given over 270 invited presentations. Dr. Solberg was named an American Cancer Society Research Scholar in 2003.

 

Dr Lye-Mun Tho

MBBS (Sydney), MRCP (UK), FRCR (UK), PhD

Dr Tho is an Associate Professor at UTAR, Malaysia and Consultant Clinical Oncologist at Beacon Hospital. His prior appointments include Associate Professor of Oncology at University Malaya and Academic Clinical Lecturer at the University of Glasgow.

He completed a PhD in molecular biology as a Cancer Research UK/Royal College of Radiologist Fellow at the Beatson Institute for Cancer Research, Glasgow. He is an investigator and collaborator on numerous clinical trials and has an ongoing interest in Neuro-Oncology, stereotactic radiosurgery and immuno-oncology.

 

Join our mailing list

If you are interested in attending the Conference and would like further information and regular updates, please register your interest below.

Key Dates

Call for Abstracts close
Closed
Early bird registration closes
11 July 2016
Author registration deadline
11 July 2016
Conference dates
11 - 14 September 2016

Sponsorship & Exhibition

Are you interested in sponsoring or exhibiting at ASNO-COGNO 2016?

Click here to express your interest.

 

Meeting Managers

Arinex Brandmark Colour RGB small

Arinex Pty Ltd
ABN 28 000 386 676
Level 10, 51 Druitt Street
Sydney NSW 2000 Australia
Tel: +61 2 9265 0700
Fax: +61 2 9267 5443
Email: asnocogno2016@arinex.com.au